-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2025-521692-31-00
5
2025-12-19
Chronic Primary Immune Thrombocytopenia
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2024-517614-14-00
4
2025-11-28
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-514401-54-00
5
2025-11-13
Chronic Primary Immune Thrombocytopenia
-
2024-515979-35-00
5
2025-11-13
Generalized Myasthenia Gravis
-
2024-519345-30-00
5
2025-11-12
IgA nephropathy
-
2025-520613-31-00
5
2025-10-31
Agitation Associated with Alzheimer’s Disease
-
2025-520747-32-00
5
2025-10-29
Mild to moderate Alzheimer’s Disease
-
2024-517671-21-00
5
2025-09-30
Coronavirus Disease 2019 (COVID-19)
-
2024-518914-18-00
4
2025-08-27
Moderate to Severely Active Ulcerative Colitis & Moderate to Severely
-
2024-517972-39-00
5
2025-08-19
Autoimmune haemolytic anaemia
-
2024-519521-37-01
10
2025-07-30
Acute ischemic stroke
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-514539-67-00
4
2025-06-27
Systemic Sclerosis
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-517457-27-00
5
2025-06-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-519116-14-00
4
2025-05-27
Asthma